Estimaciones de analistas de Wall Street para Cytosorbents Corporation (CTSO): precio objetivo de consenso, recomendaciones de compra/mantener/venta y previsiones de ingresos, BPA y EBITDA para los próximos ejercicios.
Sorpresas de Resultados Recientes
| Fecha | BPA Real | BPA Estimado | vs Est. |
|---|---|---|---|
| 2026-11-12 | $-0.90 | ||
| 2026-08-06 | $-1.40 | $-0.80 | -75.0% |
| 2026-05-13 | $-0.08 | $-0.06 | -33.3% |
| 2026-03-25 | $-0.09 | $-1.00 | +91.0% |
| 2025-11-13 | $-0.04 | $-1.20 | +96.7% |
| 2025-08-07 | $-0.05 | $-0.07 | +28.6% |
| 2025-05-14 | $-0.02 | $-1.60 | +98.8% |
| 2025-03-13 | $-0.60 | $-1.00 | +40.0% |
Ratios de valoración
| Precio / Valor contable | -23.96 |
| EV / EBITDA | -2.98 |
| Rentabilidad por dividendo | 0.00% |
Cuenta de Resultados (10 años)
| Año | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Ingresos | $8.2M | $13.4M | $20.3M | $22.8M | $39.5M | $40.1M | $34.7M | $31.1M | $35.6M | $37.1M |
| Coste de Ventas | $4.0M | $5.5M | $7.5M | $7.4M | $11.1M | $11.0M | $14.0M | $9.1M | $10.7M | $10.6M |
| Beneficio Bruto | $4.3M | $7.9M | $12.8M | $15.4M | $28.4M | $29.1M | $20.7M | $22.0M | $24.9M | $26.5M |
| I+D | $4.8M | $4.0M | $7.7M | $12.1M | $8.8M | $16.4M | $15.1M | $15.6M | $7.6M | $5.1M |
| Generales y Administrativos | $12.3M | $15.4M | $22.9M | $24.5M | $31.5M | $38.5M | $2.8M | $38.3M | $33.7M | $35.6M |
| Gastos Operativos | $15.7M | $17.7M | $28.3M | $34.4M | $38.8M | $51.8M | $52.3M | $53.9M | $41.3M | $40.7M |
| Beneficio Operativo | -$11.5M | -$9.8M | -$15.6M | -$19.0M | -$10.4M | -$22.7M | -$31.5M | -$31.9M | -$16.5M | -$14.2M |
| EBITDA | -$11.9M | -$8.2M | -$16.0M | -$18.7M | -$9.7M | -$24.2M | -$30.0M | -$27.9M | -$19.3M | -$4.4M |
| Gastos por Intereses | $231804 | $749076 | $1.5M | $1.0M | $1.2M | 0 | 0 | $157891 | $1.4M | $2.6M |
| Beneficio Antes de Impuestos | -$12.3M | -$9.1M | -$17.8M | -$20.4M | -$9.0M | -$25.3M | -$33.9M | -$30.1M | -$22.4M | -$8.6M |
| Impuestos | -$318550 | -$676739 | -$619546 | -$1.1M | -$1.1M | -$736003 | -$1.1M | -$813739 | -$1.7M | -$401000 |
| Beneficio Neto | -$11.9M | -$8.5M | -$17.2M | -$19.3M | -$7.8M | -$24.6M | -$32.8M | -$29.2M | -$20.7M | -$8.2M |
| BPA | $-9.40 | $-6.20 | $-11.20 | $-12.00 | $-4.00 | $-11.40 | $-15.00 | $-13.00 | $-7.60 | $-2.60 |
| BPA Diluido | $-9.40 | $-6.20 | $-11.20 | $-12.00 | $-4.00 | $-11.40 | $-15.00 | $-13.00 | $-7.60 | $-2.60 |
| Acciones en Circulación (Diluidas) | $1.3M | $1.4M | $1.5M | $1.6M | $1.9M | $2.2M | $2.2M | $2.2M | $2.7M | $3.1M |
Precio
| Precio | $5.73 |
| Capitalización | $18M |
| Bolsa | NASDAQ |
| País | US |
Empresas relacionadas: BDMD · BDSX · ECOR · ICCM · MDAI · NMTC · SER
Explorar sector: Healthcare · Medical - Devices
Más secciones de CTSO: Resumen · Financieros · Valoración · Estadísticas · Técnico · Propiedad · Noticias · Eventos
Descubre más: Radar — señales de acciones infravaloradas · Academia de Inversión — aprende a analizar acciones